Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

Plant-strengthening agent enhances natural ability of plants to survive
2015-07-27

Drought, diseases, and fungi. These are factors that farmers have no control over, and they often have to watch despondently as their crops are damaged. In addition, the practice of breeding plants in special and strictly-controlled conditions, has resulted in crops losing the chemical ability to protect themselves in nature.

Researchers in the Department of Soil, Crop, and Climate Sciences at the University of the Free State (UFS) have developed an organic agent that restores this chemical imbalance in plants. It enables the plant to build its own resistance against mild stress factors, and thus ensures increased growth and yield by the plant.

ComCat®, a plant-strengthening agent, is the result of extensive research by the German company, Agraforum AG, together with the UFS. Commercialisation was initially limited to Europe, while research was done at the UFS.

“Plants have become weak because they were grown specially and in isolation. They can’t protect themselves any longer,” says Dr Elmarie van der Watt from the department.

Dr Van der Watt says that, in nature, plants communicate by means of natural chemicals as part of their resistance mechanisms towards various stress conditions. These chemicals enable them to protect themselves against stress conditions, such as diseases and fungi (biotic conditions) or wind and droughts (abiotic conditions).

Most wild plant varieties are usually well-adapted to resist these stress factors. However, monoculture crops have lost this ability to a large extent.

The European researchers extracted these self-protection chemicals from wild plants, and made them available to the UFS for research and development.

“This important survival mechanism became dormant in monoculture crops. ComCat® wakes the plant up and says ‘Hey, you should start protecting yourself’.”

Research over the last few years has shown that the agent, applied mostly as a foliar spray, subsequently leads to better seedlings, as well as to growth, and yields enhancement of various crops. This is good news for the agricultural sector as it does not induce unwanted early vegetative growth that could jeopardise the final yield ? as happened in the past for nitrogen application at an early growth stage.

“The use of synthetic agents, such as fungicides which contain copper, are now banned. Nowadays, options for natural and organic agriculture is being investigated. This product is already widely used in Europe, but because farmers are often swamped by quacks, the South African market is still somewhat sceptical.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept